A promising new medicine against heart disease fails unexpectedly

An experimental drug called pelacarsen failed to reduce heart attack and stroke risks in a major clinical trial, despite successfully lowering levels of the protein Lp(a). Researchers expressed disappointment as the drug did not provide the expected health benefits for patients with cardiovascular disease.
Why it matters
Cardiovascular disease remains the leading cause of death globally, and this failure highlights the ongoing difficulty in finding effective treatments for patients who already manage traditional risk factors.
Planet Flem/Digital Vision Vectors//Getty Images For stories on the science of healthy living, subscribe to NPR's Health newsletter.
An experimental drug doctors hoped would be the next big advance in preventing heart attacks and strokes failed a crucial test, researchers reported Saturday.
Living Better Heart disease deaths declined. And here's how to reduce your risk of the #1 killer The medicine, which reduces levels of a particle in the blood associated with heart attacks and strokes, didn't protect volunteers in a closely watched study.
"I was shocked. I had high hopes for success," says Steven Nissen , a cardiologist at the Cleveland Clinic who led the study. "Cardiovascular disease is still the leading cause of death in developed countries. And so we really were hoping to find additional therapies that would reduce risk."
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in